The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients.
Salehzadeh S, Guerrini F, Pizzano U, Grassi S, Ciabatti E, Iovino L, Buda G, Caracciolo F, Benedetti E, Orciuolo E, Pelosini M, Consani G, Carulli G, Metelli MR, Martini F, Mazziotta F, Mazzantini E, Rossi P, Tavarozzi R, Ricci F, Petrini M, Galimberti S.
Salehzadeh S, et al. Among authors: iovino l.
Cancer Cell Int. 2019 Apr 4;19:83. doi: 10.1186/s12935-019-0807-0. eCollection 2019.
Cancer Cell Int. 2019.
PMID: 30992690
Free PMC article.